
CAMP4 THERAPEUTICS CORPORATION
CAMP · NASDAQ · Healthcare / Biotechnology
3.80USD-0.29 (-7.09%)
Price History
Full chartMarket Stats
Previous Close4.09
Open4.13
Day Range3.75 – 4.13
52-Week Range2.85 – 7.75
Volume46.16K
Market Cap245.99M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.31
Dividend Yield0.00%
50-Day Avg4.07
200-Day Avg4.53
About
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Joshua Mandel-Brehm
- Employees48
- HeadquartersOne Kendall Square, Cambridge, MA, United States, 02139, USA
- Websitehttps://www.camp4tx.com
Leadership
- Mr. Joshua Mandel-BrehmCEO, President & Director · b. 1983
- Dr. Richard A. Young Ph.D.Founder & Independent Director · b. 1954
- Ms. Kelly GoldChief Financial Officer · b. 1977
- Dr. Yuri Maricich M.B.A., M.D.Chief Medical Officer · b. 1981
- Dr. Leonard I. Zon M.D.Founder & Chairman of Scientific Advisory Board
- Mr. Caleb MooreChief Business Operations Officer
- Dr. Daniel Tardiff Ph.D.Chief Scientific Officer · b. 1980
- Ms. Michelle GatesSenior VP & Chief People Officer
- Ms. Alla Sigova Ph.D.Senior Vice President of Platform
- Dr. Satya Kuchimanchi Ph.D.Senior Vice President of Technical Operations
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Market Cap245.99M
Enterprise Value150.11M
Trailing P/E0.00
Forward P/E0.00
Price / Sales58.35
Price / Book9.11
EPS-2.31
Book Value-0.013
Revenue (TTM)4.22M
Gross Profit (TTM)-34.47M
EBITDA-50.56M
Profit Margin0.00%
Operating Margin-752.11%
Return on Equity-545.85%
Return on Assets-45.25%
Shares Outstanding62.75M
Shares Float38.45M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%
Analyst Ratings
Strong Buy
Based on 5 analystsTarget 9.92
- Strong Buy3
- Buy2
Ownership Breakdown
- Institutions
- 79.70%
- Insiders
- 9.65%
- Retail / Other
- 10.65%
Top Institutional Holders
- HHG PLC6.31M10.05%
- 5AM Venture Management, LLC5.87M9.35%
- FMR Inc4.93M7.86%
- Vivo Capital, LLC4.25M6.77%
- Balyasny Asset Management LLC2.63M4.19%
- Adage Capital Partners Gp LLC1.96M3.12%
- Trails Edge Capital Partners, LP1.93M3.08%
- Vanguard Capital Management, LLC1.53M2.45%
- Enavate Sciences GP, LLC1.43M2.27%
- Stonepine Capital Management Llc1.39M2.21%
- Harbourvest Partners, LLC1.27M2.03%
- SILVERARC CAPITAL MANAGEMENT, LLC653.59K1.04%
- BlackRock Inc456.37K0.73%
- Geode Capital Management, LLC382.82K0.61%
- SummitTX Capital, L.P339.52K0.54%
Top Fund Holders
- Fidelity Select Biotechnology1.33M2.11%
- Vanguard MStar Total Stk Mkt Idx Invest1.24M1.97%
- iShares Russell 2000 ETF496.25K0.79%
- Fidelity Growth Company Fund399.58K0.64%
- Fidelity Small Cap Index342.26K0.55%
Stock Splits
- Mar 25, 19962:1